Glaxosmithkline and Elbion to Collaborate on Development and Commercialisation of a new DE IV Inhibitor

25-Jan-2005

GlaxoSmithKline plc (GSK) and Elbion AG announce that they have signed a worldwide agreement to collaborate on the development and commercialisation of elbion's phosphodiesterase (PDE) IV inhibitor, AWD 12-281 and associated back-up compounds. AWD 12-281 is currently in phase II clinical studies by the intra nasal delivery route for allergic rhinitis and phase I studies by inhaled delivery for asthma and chronic obstructive pulmonary disease (COPD).

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances